Death rates in the U.S. due to Krabbe disease and related leukodystrophy and lysosomal storage diseases

Authors

  • Amy L. Barczykowski,

    1. Population Health Observatory, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York
    Search for more papers by this author
  • Alexander H. Foss,

    1. Population Health Observatory, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York
    Search for more papers by this author
  • Patricia K. Duffner,

    1. Department of Neurology, Hunter James Kelly Research Institute, School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, New York
    Search for more papers by this author
  • Li Yan,

    1. Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, New York
    Search for more papers by this author
  • Randy L. Carter

    Corresponding author
    1. Population Health Observatory, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York
    2. Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York
    • Department of Biostatistics, 725 Kimball Tower, 3435 Main Street, Buffalo, NY 14214.
    Search for more papers by this author

  • How to Cite this Article: Barczykowski AL, Foss AH, Duffner PK, Yan L, Carter RL. 2012. Death rates in the U.S. due to Krabbe disease and related leukodystrophy and lysosomal storage diseases. Am J Med Genet Part A 158A: 2835–2842.

  • Conflict of Interest Statement: All authors are without conflict of interests.

Abstract

Leukodystrophies (LD) and lysosomal storage disorders (LSD) have generated increased interest recently as targets for newborn screening programs. Accurate epidemiological benchmarks are needed in the U.S. Age-specific mortality rates were estimated for Krabbe disease (KD) and nine related disorders. U.S. mortality records with E75.2 cause of death code during 1999–2004 were collected from 11 open record states. All E75.2 deaths in the United States were distributed into specific disease type based on proportions observed in these states. Yearly population sizes were obtained from the CDC and averaged. Mortality rates (per million individuals per year) by age group for the specific diseases were (for <5 or ≥5 years): Pelizaeus-Merzbacher (0.037/0.033); sudanophilic leukodystrophy (SLD) (0.037/0.004); Canavan (0.037/0.011), Alexander (0.147/0.022); Krabbe (0.994/0.007); metachromatic leukodystrophy (0.331/0.135); Fabry (0.000/0.124); Gaucher (0.221/0.073); Niemann–Pick (NP) (0.442/0.088); multiple sulfatase (0.000/0.004). This is the first report of mortality rates for the LD/LSD diseases in the U.S. Approximated birth prevalence rate for the early infantile Krabbe phenotype (onset 0–6 months) was based on the <5 year old mortality rate of one early infantile case per 244,000 births, which matches the 1 in 250,000 observed in the NYS newborn screening program as of 2011. It should be noted however that the NYS calculation refers only to the early infantile phenotype and does not include the majority of babies identified in the program with low GALC and two mutations who have remained clinically normal. It is presumed that most, if not all, will develop later onset forms of the disease, but this is by no means certain. © 2012 Wiley Periodicals, Inc.

Ancillary